Alkem Laboratories has denied allegations by the CDSCO that certain batches of its products, Pan-D and Clavam 625, failed to meet quality standards. The company asserted that the samples in question were fake after comparing them with actual batches. Alkem’s stock price saw a slight decline before closing marginally lower.
Related Posts
Tata Motors joins hands with ESAF Small Finance Bank for vehicle finance
Tata Motors has entered into a partnership with ESAF Small Finance Bank to provide financing solutions for its commercial vehicle customers. Initially targeting small and […]
How Trump’s tariff plans will impact China’s economy this time
Donald Trump’s proposed 60% tariffs on Chinese imports pose significant economic threats to China. China’s property sector crisis, deflationary pressures, and unsustainable local government debt […]
Swiggy trims valuation target to $11.3 billion for IPO
Swiggy plans a Rs 11,327 crore IPO on Nov 6, aiming for $11.3 billion valuation, adjusted from up to $13 billion due to market conditions. […]